In a subgroup analysis of the HER2-single-type tumors, pertuzumab treatment was associated with lower hazard of breast cancer death in the presence of competing risks (aHR 0.392, 95% CI 0.19–0.81, p = 0.012, n = 555; Fig. 4c). This evidence concerns the gene ERBB2 and breast cancer.